Cytek Biosciences, Inc. · NASDAQ:CTKB
Cytek Biosciences — Q4 2025 Earnings Presentation
14 slides from Cytek Biosciences's earnings presentation, Feb 26, 2026
Slide 1: Q4 and Full Year 2025 Earnings Presentation
Q4 and Full Year 2025 Earnings Presentation February 26, 2026
Slide 2: Safe Harbor Statement
Safe Harbor Statement This presentation and the related conference call and webcast contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, among others, statements regarding Cytek’s future financial performance, including its outlook
Slide 3: Q4 2025 Revenue Results
Q4 2025 Revenue Results1 Product Revenue Service Revenue $62.1M $57.5 +8% Y/Y Q4 2025 Commentary -1% Y/Y $52.3 +2% Y/Y $45.6 $41.5 -2% Y/Y Q4 was the highest quarterly revenue -8% Y/Y ever achieved at Cytek $46.6 $45.0 $38.1 $31.4 Driven by a continuation of trends $28.1 seen in the third quarter 2,
Slide 4: Revenue by Geographic Region
Revenue by Geographic Region1 Other APAC EMEA Q4 2025 Commentary United States $62.1M US: Revenue was up 5% Y/Y driven by shifting $57.5 +8% Y/Y sentiment in academic/government, partially -1% Y/Y $52.3 $3.7 offset by decline in instrument sales to +2% Y/Y $5.3 $45.6 pharma/biotech $13.2 $41.5 -2% Y
Slide 5: Stabilized Product Revenue + Service Growth = Improved Overall Growth
Stabilized Product Revenue + Service Growth = Improved Overall Growth1 $114.4M $109.0M $91.5M $87.1M $24.4 $29.7 $22.8 $27.5 -5% +5% Y/Y Y/Y $84.6 $84.7 $68.7 $59.5 1H 2024 1H 2025 2H 2024 2H 2025 Product Service 1. As of 12/31/2025 2. EMEA = Europe, Middle East, & Africa 3. APAC = Asia-Pacific; Res
Slide 6: Our Strategic Business Pillars
Our Strategic Business Pillars1 Instruments Applications Bioinformatics Clinical1 Expanded to a total installed base of 3,664 Cytek instruments, adding 208 units in the fourth quarter Unit placements of Cytek’s Aurora CS system grew 22% in 2025 over the prior year Launched the Cytek Aurora Evo syste
Slide 7: Recurring Revenue Businesses Continue to Grow Steadily
Recurring Revenue Businesses Continue to Grow Steadily1 Full Year 2024 Full Year 2025 29% of Total Revenue 34% of Total Revenue $132.1 $143.0 21% Y/Y Growth $57.5 $69.4 FY 2024 FY 2024 Service & Reagent Other Revenue 1. Recurring revenue is comprised of service and reagent revenue; Other revenue is
Slide 8: Q4 2025 Financial Overview
Q4 2025 Financial Overview in millions Q4 2024 Q4 2025 Special Items Total Revenue $57.5 $62.1 1. Includes $2.6M expense reduction from license & Gross Profit $33.7 $32.9 royalty settlement liability adjustment Gross Margin 59% 53% 2. Includes $8.8M benefit from license & royalty settlement liabilit
Slide 9: Full Year 2025 Financial Overview
Full Year 2025 Financial Overview in millions 2024 2025 Special Items Total Revenue $200.5 $201.5 1. Includes $2.6M expense reduction from license Gross Profit $111.1 $104.5 & royalty settlement liability adjustment Gross Margin 55% 52% 2. Includes $0.7M write-off of non-recurring deferred offering
Slide 10: Initiating Full Year 2026 Revenue Guidance
FY 2026 Revenue1 Initiating Full Year 2026 Revenue $205 - $212 million Guidance +2 to +5% Y/Y growth 1. Assumes no change from current currency exchange rates or 2025 tariff policy 10
Slide 11: 2026 Strategic Priorities
2026 Strategic Priorities Attractive Financial Profile Growing Recurring Revenue Well-positioned to Technology Platform deliver long-term Leader Drive reagent and value through Global Diversification service businesses differentiated Advance technological benefitting from technology portfolio, leade
Slide 12: Appendix
“CYTE K* TRANSCEND THE CONVENTIONAL. Appendix
Slide 13: Reconciliation of GAAP to Non-GAAP Measures (Unaudited)
Reconciliation of GAAP to Non-GAAP Measures (Unaudited) Three months ended Twelve months ended (In thousands) December 31, 2025 December 31, 2024 December 31, 2025 December 31, 2024 GAAP gross profit $ 32,885 $ 33,652 $ 104,460 $ 111,106 Stock based compensation $ 893 $ 1,139 $ 3,995 $ 4,438 Amortiz
Slide 14: Thank You
e - TRANSCEND THE CONVENTIONAL ‘Thank You